ENTX NASDAQ
Credit Risk of going bust: lower than 63% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Total debt $425K against a stock market value of $497.2M.
Distance to default 6.62 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $212K (short-term plus half of long-term), stock volatility 109.0%; Altman Z'' -21.44. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Jerusalem, JM 9112002
IL
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Camisasca Riccardo P | 0 | — | 2026-08-18 | |
| Malca Yonatan | A-Award | 22,815 | — | 2026-08-07 |
| Taitel Haya | A-Award | 20,790 | — | 2026-08-07 |
| Ellis Sean | A-Award | 20,034 | — | 2026-08-07 |
| Ellis Sean | A-Award | 40,000 | $1.37 | 2026-08-07 |